316 related articles for article (PubMed ID: 32568281)
1. Changing paradigms in the management of gout.
Nuki G; Riches P
J R Coll Physicians Edinb; 2020 Jun; 50(2):124-132. PubMed ID: 32568281
[TBL] [Abstract][Full Text] [Related]
2. Gout - An update of aetiology, genetics, co-morbidities and management.
Robinson PC
Maturitas; 2018 Dec; 118():67-73. PubMed ID: 30415758
[TBL] [Abstract][Full Text] [Related]
3. Advances in pharmacotherapy for the treatment of gout.
Robinson PC; Dalbeth N
Expert Opin Pharmacother; 2015 Mar; 16(4):533-46. PubMed ID: 25547991
[TBL] [Abstract][Full Text] [Related]
4. Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
Keenan RT
Clin Ther; 2017 Feb; 39(2):430-441. PubMed ID: 28089200
[TBL] [Abstract][Full Text] [Related]
5. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
7. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Cutolo M; Cimmino MA; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
[TBL] [Abstract][Full Text] [Related]
8. [Gout].
Tausche AK
Internist (Berl); 2021 May; 62(5):513-525. PubMed ID: 33721041
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Gupta MK; Singh JA
Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
[TBL] [Abstract][Full Text] [Related]
10. The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
Smolen LJ; Gahn JC; Mitri G; Shiozawa A
Clin Ther; 2016 Jul; 38(7):1710-25. PubMed ID: 27269247
[TBL] [Abstract][Full Text] [Related]
11. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis.
Borghi C; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):983-92. PubMed ID: 27010159
[TBL] [Abstract][Full Text] [Related]
12. Major unanswered questions in the clinical gout field.
Stamp LK
Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541
[TBL] [Abstract][Full Text] [Related]
13. [Gout: an overview of available urate lowering therapies].
Richette P
Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581
[TBL] [Abstract][Full Text] [Related]
14. Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
Graham GG; Stocker SL; Kannangara DRW; Day RO
Curr Rheumatol Rep; 2018 Jun; 20(8):47. PubMed ID: 29931553
[TBL] [Abstract][Full Text] [Related]
15. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
Zhang T; Pope JE
Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
Lertnawapan R; Jatuworapruk K
Clin Rheumatol; 2021 Jan; 40(1):255-262. PubMed ID: 32607660
[TBL] [Abstract][Full Text] [Related]
18. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
Singh JA; Akhras KS; Shiozawa A
Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
[TBL] [Abstract][Full Text] [Related]
20. Gout.
Dalbeth N; Choi HK; Joosten LAB; Khanna PP; Matsuo H; Perez-Ruiz F; Stamp LK
Nat Rev Dis Primers; 2019 Sep; 5(1):69. PubMed ID: 31558729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
